Gremubamab, previously known as MEDI3902 , represents a novel therapeutic strategy targeting BCMA in hematological cancers . The molecule functions as an immune effector – specifically, a humanized https://oisiujxq475472.activoblog.com/52799933/gremubamab-a-deep-investigation-into-medi3902-s-possibility